Imperial College London
Portrait Picture

ProfessorDeborahAshby

Faculty of Medicine, School of Public Health

Dean of the Faculty of Medicine
 
 
 
//

Contact

 

+44 (0)20 7594 8704deborah.ashby Website

 
 
//

Location

 

2.15Faculty BuildingSouth Kensington Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Mason:2016:10.1016/j.clon.2016.05.011,
author = {Mason, MD and Moore, R and Jones, G and Lewis, G and Donovan, JL and Neal, DE and Hamdy, FC and Lane, JA and Staffurth, JN and Bonnington, S and Bradshaw, L and Cooper, D and Elliott, E and Herbert, P and Holding, P and Howson, J and Jones, M and Lennon, T and Lyons, N and Moody, H and Plumb, C and O'Sullivan, T and Salter, L and Tidball, S and Thompson, P and Adam, T and Askew, S and Atkinson, S and Baynes, T and Blaikie, J and Brain, C and Breen, V and Brunt, S and Bryne, S and Bythem, J and Clarke, J and Cloete, J and Dark, S and Davis, G and De, La Rue R and Denizot, J and Dewhurst, E and Dimes, A and Dixon, N and Ebbs, P and Emmerson, I and Ferguson, J and Gadd, A and Geoghegan, L and Grant, A and Grant, C and Gray, C and Godfrey, R and Goodwin, L and Hall, S and Hart, L and Harvey, A and Hoult, C and Hawkins, S and Holling, S and Innes, A and Kilner, S and Marshall, F and Mellen, L and Moore, A and Napier, S and Needham, J and Pearse, K and Pisa, A and Rees, M and Richards, E and},
doi = {10.1016/j.clon.2016.05.011},
journal = {Clinical Oncology},
pages = {e92--e100},
title = {Radiotherapy for Prostate Cancer: is it ‘what you do’ or ‘the way that you do it’? A UK Perspective on Technique and Quality Assurance},
url = {http://dx.doi.org/10.1016/j.clon.2016.05.011},
volume = {28},
year = {2016}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - © 2016Aims The treatment of prostate cancer has evolved markedly over the last 40 years, including radiotherapy, notably with escalated dose and targeting. However, the optimal treatment for localised disease has not been established in comparative randomised trials. The aim of this article is to describe the history of prostate radiotherapy trials, including their quality assurance processes, and to compare these with the ProtecT trial. Materials and methods The UK ProtecT randomised trial compares external beam conformal radiotherapy, surgery and active monitoring for clinically localised prostate cancer and will report on the primary outcome (disease-specific mortality) in 2016 following recruitment between 1999 and 2009. The embedded quality assurance programme consists of on-site machine dosimetry at the nine trial centres, a retrospective review of outlining and adherence to dose constraints based on the trial protocol in 54 participants (randomly selected, around 10% of the total randomised to radiotherapy, n = 545). These quality assurance processes and results were compared with prostate radiotherapy trials of a comparable era. Results There has been an increasingly sophisticated quality assurance programme in UK prostate radiotherapy trials over the last 15 years, reflecting dose escalation and treatment complexity. In ProtecT, machine dosimetry results were comparable between trial centres and with the UK RT01 trial. The outlining review showed that most deviations were clinically acceptable, although three (1.4%) may have been of clinical significance and were related to outlining of the prostate. Seminal vesicle outlining varied, possibly due to several prostate trials running concurrently with different protocols. Adherence to dose constraints in ProtecT was considered acceptable, with 80% of randomised participants having two or less deviations and planning target volume coverage was excellent. Conclusion The ProtecT trial quality assur
AU  - Mason,MD
AU  - Moore,R
AU  - Jones,G
AU  - Lewis,G
AU  - Donovan,JL
AU  - Neal,DE
AU  - Hamdy,FC
AU  - Lane,JA
AU  - Staffurth,JN
AU  - Bonnington,S
AU  - Bradshaw,L
AU  - Cooper,D
AU  - Elliott,E
AU  - Herbert,P
AU  - Holding,P
AU  - Howson,J
AU  - Jones,M
AU  - Lennon,T
AU  - Lyons,N
AU  - Moody,H
AU  - Plumb,C
AU  - O'Sullivan,T
AU  - Salter,L
AU  - Tidball,S
AU  - Thompson,P
AU  - Adam,T
AU  - Askew,S
AU  - Atkinson,S
AU  - Baynes,T
AU  - Blaikie,J
AU  - Brain,C
AU  - Breen,V
AU  - Brunt,S
AU  - Bryne,S
AU  - Bythem,J
AU  - Clarke,J
AU  - Cloete,J
AU  - Dark,S
AU  - Davis,G
AU  - De,La Rue R
AU  - Denizot,J
AU  - Dewhurst,E
AU  - Dimes,A
AU  - Dixon,N
AU  - Ebbs,P
AU  - Emmerson,I
AU  - Ferguson,J
AU  - Gadd,A
AU  - Geoghegan,L
AU  - Grant,A
AU  - Grant,C
AU  - Gray,C
AU  - Godfrey,R
AU  - Goodwin,L
AU  - Hall,S
AU  - Hart,L
AU  - Harvey,A
AU  - Hoult,C
AU  - Hawkins,S
AU  - Holling,S
AU  - Innes,A
AU  - Kilner,S
AU  - Marshall,F
AU  - Mellen,L
AU  - Moore,A
AU  - Napier,S
AU  - Needham,J
AU  - Pearse,K
AU  - Pisa,A
AU  - Rees,M
AU  - Richards,E
AU  - Robson,L
AU  - Roxburgh,J
AU  - Samuel,N
AU  - Sharkey,I
AU  - Slater,M
AU  - Smith,D
AU  - Taggart,P
AU  - Taylor,H
AU  - Taylor,V
AU  - Thomas,A
AU  - Tomkies,B
AU  - Trewick,N
AU  - Ward,C
AU  - Walker,C
AU  - Williams,A
AU  - Woodhouse,C
AU  - Wyber,E
AU  - Aning,J
AU  - Bollina,P
AU  - Catto,J
AU  - Doble,A
AU  - Doherty,A
AU  - Durkan,G
AU  - Gillatt,D
AU  - Hughes,O
AU  - Kocklebergh,R
AU  - Kouparis,A
AU  - Kynaston,H
DO  - 10.1016/j.clon.2016.05.011
EP  - 100
PY  - 2016///
SN  - 0936-6555
SP  - 92
TI  - Radiotherapy for Prostate Cancer: is it ‘what you do’ or ‘the way that you do it’? A UK Perspective on Technique and Quality Assurance
T2  - Clinical Oncology
UR  - http://dx.doi.org/10.1016/j.clon.2016.05.011
VL  - 28
ER  -
Download